| Prev Close | 20.14 |
| Open | 20.24 |
| Day Low/High | 20.03 / 21.00 |
| 52 Wk Low/High | 13.88 / 33.44 |
| Volume | 936.94K |
| Avg Volume | 851.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 52.45M |
| Market Cap | 1.11B |
| EPS | 0.50 |
| P/E Ratio | 87.96 |
| Div & Yield | N.A. (N.A) |
The market could take off on a bullish surprise, but binary events are always tough to trade.
Investors eyeing a purchase of Vanda Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 80 cents.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Vanda Pharmaceuticals (Nasdaq:VNDA) has been downgraded by TheStreet Ratings from from a hold to sell.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
These stocks look poised to break out and trade significantly higher from current levels.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Vanda Pharmaceuticals (Nasdaq:VNDA) has been upgraded by TheStreet Ratings from a sell to hold.
Vanda's schizophrenia drug closes 2010 with just $31 million in sales, far below expectations.
Clinical Data's new antidepressant is approved but bulls want the company to be sold for an even higher premium while bears say any deal is unlikely.
These five-star stocks trade at huge discounts to fair value and could soar in 2011.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.
Vanda's Fanapt is treated roughly in the new psychiatrists' 'bible', further hurting the drug's launch efforts.
Here's a list of May's potentially stock-moving biotech events.
Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.
Biotech's first-quarter earnings season kicks off next week. Here are earnings summaries for nine revenue-generating biotech stocks.
Biotech columnist Feuerstein answers readers' questions about Generex, Cell Therapeutics and other stocks.
Expecting limited upside, a call seller boosts volume in Vanda Pharmaceuticals.
A look back at 2009's best- and worst-performing bitoech stocks.
Diedrich Coffee is up 9,580%, RHI Entertainment lands at the bottom, down 96%.
Bulls were hoping for a Vanda takeover.
Vanda Pharmaceuticals entered into an exclusive license agreement with Novartis to commercialize and develop schizophrenia drug Fanapt in the U.S. and Canada.
Novartis to pay Vanda up to $465 million for rights to sell schizophrenia drug in US, Canada
Vanda's chances of getting acquired seem to be drying up, according to two analysts.
Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.
Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.
